U.S. market Closed. Opens in 10 hours 5 minutes

CODX | Co-Diagnostics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.2000 - 1.2288
52 Week Range 1.0000 - 2.2300
Beta 1.47
Implied Volatility 151.97%
IV Rank 23.39%
Day's Volume 23,897
Average Volume 249,220
Shares Outstanding 31,911,000
Market Cap 38,931,420
Sector Healthcare
Industry Medical - Devices
IPO Date 2017-07-12
Valuation
Profitability
Growth
Health
P/E Ratio -0.97
Forward P/E Ratio -253.00
EPS -1.26
1YR Price Target 6.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 155
Country USA
Website CODX
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
*Chart delayed
Analyzing fundamentals for CODX we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is very good and Health is strong. For more detailed analysis please see CODX Fundamentals page.

Watching at CODX technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on CODX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙